Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease
Conditions
Interventions
PET MPI
SPECT MPI
+1 more
Locations
53
United States
Vascular Biology and Hypertension Program, University of Alabama at Birmingham
Birmingham, Alabama, United States
University of California- Los Angeles
Los Angeles, California, United States
Keck Hospital of USC
Los Angeles, California, United States
VA Greater Los Angeles Health Care System
Los Angeles, California, United States
VA San Diego Health System
San Diego, California, United States
UCSF
San Francisco, California, United States
Start Date
June 5, 2018
Primary Completion Date
May 5, 2022
Completion Date
May 5, 2022
Last Updated
July 12, 2023
NCT07444697
NCT07237685
NCT06659367
NCT06701032
NCT07473596
NCT07374718
Lead Sponsor
GE Healthcare
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions